Literature DB >> 7566174

A role for CD95 ligand in preventing graft rejection.

D Bellgrau1, D Gold, H Selawry, J Moore, A Franzusoff, R C Duke.   

Abstract

Testis is a remarkable immune-privileged site, long known for its ability to support allogeneic and xenogeneic tissue transplants. Here we have investigated the molecular basis for testis immune privilege. Testis grafts derived from mice that can express functional CD95 (Fas or Apo-1) ligand survived indefinitely when transplanted under the kidney capsule of allogeneic animals, whereas testis grafts derived from mutant gld mice, which express non-functional ligand, were rejected. Further analysis of testis showed that CD95 ligand messenger RNA is constitutively expressed by testicular Sertoli cells, and that Sertoli cells from normal mice, but not gld mice, were accepted when transplanted into allogeneic recipients. CD95 ligand expression in the testis probably acts by inducing apoptotic cell death of CD95-expressing, recipient T cells activated in response to graft antigens. These findings indicate that CD95 ligand could be used to create immune-privileged tissue for a variety of transplant uses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7566174     DOI: 10.1038/377630a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  179 in total

Review 1.  The role of self-recognition in receptor repertoire development. Members of the Janeway Laboratory.

Authors:  C A Janeway
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

3.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

Review 4.  New approaches to inducing the death of alloreactive lymphocytes.

Authors:  S M Krams
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 5.  Gene therapy for restenosis.

Authors:  R C Smith; K Walsh
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

Review 6.  Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells.

Authors:  Huang-Ge Zhan; John D Mountz; Martin Fleck; Tong Zhou; Hui-Chen Hsu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection.

Authors:  J Ehrmann; D Galuszková; J Ehrmann; I Krc; V Jezdinská; B Vojtések; P G Murray; Z Koláo
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

8.  Frequent Fas gene mutations in testicular germ cell tumors.

Authors:  Hitoshi Takayama; Tetsuya Takakuwa; Yuichi Tsujimoto; Yoichi Tani; Norio Nonomura; Akihiko Okuyama; Shigekazu Nagata; Katsuyuki Aozasa
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 9.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

Review 10.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.